Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • July 09, 2018 10:05 AM | Anonymous

    AAPA 

    Equip yourself with the latest evidence-based knowledge on several forms of LARC contraception options with this free activity on LARC options. It will help you evaluate safety and efficacy data, understand the common concerns and priorities related to contraception, and have more informed discussions with patients. Plus, earn AAPA Category 1 Self-Assessment CME! 

    Get started today.

  • June 28, 2018 1:34 PM | Anonymous

    HealthDay News 

    Using automated breast density measurements, Norwegian researchers were able to more precisely confirm that women with dense breasts have a higher risk of breast cancer.

    The study included more than 100,000 women and more than 300,000 screening exams.

    "We found that screening examinations of women having dense breasts showed higher rates of recall and biopsy, and higher odds of screen-detected and interval breast cancers than women with non-dense breasts," said the study's senior author, Solveig Hofvind. She is a researcher and head of BreastScreen Norway for the Cancer Registry of Norway.

    Dense breasts pose a challenge when it comes to cancer screening, because dense tissue shows up white on a mammogram. That's also how breast tumors look on a mammogram. Dense breast tissue can actually hide or mask cancers, according to Hofvind.

    The findings were published June 26 in Radiology.

    Dr. Liane Philpotts wrote an accompanying editorial. She is chief of breast imaging at the Yale School of Medicine.

    "Dense breasts are not something that a patient feels. You can only tell if someone has dense breast tissue on a mammogram," Philpotts said.

    Radiologists identify breast density using a standardized scoring technique from the American College of Radiology (ACR). The scoring system runs from A to D. A woman with an A or B doesn't have dense breasts, but someone with a C or D does, she explained.

    About half of American women who are screened for breast cancer have dense breast tissue. As women age, their breasts often become less dense, Philpotts said.

    Instead of using the ACR technique, which relies on a radiologist's subjective judgment, the new study used automated software -- known as automated volumetric analysis -- to classify breast density.

    The Norwegian women in the study were between 50 and 69 years old. The automated software found dense breasts in 28 percent of their screening tests.

    The rates of cancer were 6.7 per 1,000 exams for women with dense breasts and 5.5 for women with non-dense breasts, according to the findings.

    "This study really shows that women with dense breasts did have more cancers. It wasn't a huge amount. It was a small increase, but it was an increase," Philpotts said.

    In addition, women with dense breasts had more interval cancers. These are cancers found between screenings -- for example, when a woman feels a lump in her breast.

    The study found that women with dense breasts were called back for more testing due to suspicious findings and were more likely to have a biopsy to check tissue for cancer than women without dense breasts.

    Women with dense breasts also tended to have larger tumors when cancer was detected -- average of 17 millimeters (mm) vs. 15 mm for women without dense breasts.

    The study also confirmed that it's harder to accurately identify breast cancers in dense breast tissue. Cancers were accurately detected in women with dense breasts 71 percent of the time compared to 82 percent for women without dense breasts.

    "Automated volumetric breast density measurements may be considered a future standard for breast cancer screening, ensuring an objective density classification," Hofvind said.

    Philpotts pointed out that the findings don't necessarily translate to a U.S. population, because the women screened in the study were older, and they were screened every other year instead of annually.

    She said more research is needed to gauge the risks and benefits of the automated software. Hofvind agreed.

    Women with dense breasts generally don't need to be screened more often, according to Philpotts. But they will need some sort of supplemental imaging such as ultrasound or MRI that's better at seeing the difference between dense tissue and cancerous tissue.

  • June 28, 2018 9:22 AM | Anonymous

    Monthly Prescribing Reference 

    Achaogen announced that the U.S. Food and Drug Administration (FDA) has approved Zemdri (plazomicin) for adults (aged at least 18 years) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae. Zemdri, an aminoglycoside antibacterial, is a once-daily intravenous (IV) infusion that was designed to resist aminoglycoside-modifying enzymes.  

    Read more.

  • June 28, 2018 9:20 AM | Anonymous

    Huddle 

    Find a PA mentor or mentee with this new, free program in Huddle. Achieve your career goals with the guidance you'll find here, or help advance your fellow PAs with advice. Grow your professional relationships and make new connections that will last. You can enroll as both a mentor and mentee — plus, you can sign up anytime throughout the year. 

    Learn more.

  • June 25, 2018 9:06 AM | Anonymous

    AAPA 

    It's that time of year when students don their caps and gowns at commencement, where, if they're lucky, they hear some inspirational words from someone who has "made it." This year, AAPA President Gail Curtis reflects on soccer star Abby Wambach's commencement address to the women of Barnard College. 

    Read more.

  • June 21, 2018 12:43 PM | Anonymous

    AAPA 

    Choosing the appropriate pharmacotherapy is essential to managing diabetes and preventing hypoglycemia in your patients with T2DM. A newly released free CME activity, Managing the Risk of Hypoglycemia in Special Patient Populations, outlines risk factors and newer treatment options. Earn AAPA Category 1 CME credit while learning about comorbid conditions that may increase the risk of hypoglycemia in these patients. Plus, don't miss bonus free self-assessment CME with two eCase Challenges! Find it all in AAPA's Learning Central. 

    Read more.

  • June 19, 2018 9:42 AM | Anonymous

    Medical News Today 

    The merits of vitamin D when it comes to cancer prevention have long been at the heart of medical debates. Where some studies have revealed that overall cancer risk is lower in people with higher levels of this vitamin, others have suggested that vitamin D has no impact on a person's vulnerability to the disease. Still, the case for ensuring that you get enough vitamin D is fairly strong.

    Read more.

  • June 19, 2018 9:39 AM | Anonymous

    JAAPA 

    Family-centered rounds is an approach to patient care that includes patients and their family members as part of the daily discussion of medical decision-making, and often also includes practitioners of supporting disciplines. This type of rounding has become increasingly popular over the past decade, as it has been shown to increase family satisfaction, improve team communication, streamline management, and reduce medical errors. Although bedside rounding lets the attending physician explain management decisions to the family, it also informs the multidisciplinary team in a collaborative manner.

    Read more.

  • June 19, 2018 9:35 AM | Anonymous

    AAPA 

    There's a lot going on in the recertification arena for PAs and physicians. Both NCCPA and AAPA have taken some important and positive steps toward improving PA recertification. Among physician groups, recertification also continues to be an important topic, and similar discussions and changes are taking place. 

    Read more. 

  • June 14, 2018 9:41 AM | Anonymous

    HemOnc Today 

    The U.S. Food and Drug Administration approved bevacizumab for use with chemotherapy, followed by bevacizumab as a single agent, for the treatment of women with advanced ovarian cancer who underwent initial surgical resection. Bevacizumab (Avastin, Genentech) is now approved for 10 indications in the United States. These include advanced cervical cancer and two forms of ovarian cancer that recurred after platinum-based chemotherapy.  

    Read more.

Powered by Wild Apricot Membership Software